Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

inistrative 194 (3) (b),(d),(g) 191

Research and development 64 - 64

Write-off of acquired IPR&D - - -

Earnings from operations 75 53 128

Interest income 5 - 5

Interest expense 32 - 32

Other (expense) income, net (8) - (8)

Earnings before income taxes

and minority interest 40 53 93

Income tax expense 17 14 (h) 31

Minority interest loss - (0) (0)

Net earnings from continuing

operations 23 39 62

Net loss from discontinued

operations, net of taxes - - -

Net earnings $23 $39 $62

Diluted

Earnings per common share -

continuing operations $0.21 $0.57

Earnings per common share -

discontinued operations $- $-

Net earnings per common share

- diluted $0.21 $0.57

Weighted average shares

- diluted 109 109

Three Months Ended March 31, 2007

Adjusted

GAAP Adjustments Earnings

Revenues:

Product sales $560 - $560

Alliance and

development revenue 25 - 25'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2
... 5, 2011 TetraLogic Pharmaceuticals , a biopharmaceutical ... treat cancer, today announced the initiation of a Phase ... candidate, TL32711, in elderly patients with acute myelogenous leukemia ... Hospital of the University of Pennsylvania and is an ...
... FRANCISCO, Calif., Dec. 5, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today said that it plans to present ... Metabolic Disorders Conference on Tuesday, December 6, 2010 at ...
... Corp. announced today that Wayne R. Gombotz, Ph.D. has ... Officer.  Dr. Gombotz brings a significant amount of ... at Immune Design.  He will oversee product development ... candidates. (Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO ...
Cached Biology Technology:TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 2TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 3Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
(Date:9/16/2014)... Fire began on September 13, 2014. The fire is ... currently over 2,300 acres in size and is mostly ... Fire was calm Monday night due to higher humidity. ... point and beginning to construct a fireline on the West ... are working on the fire: , 7 20-person Crews, 4 ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... UT Southwestern Medical Center researchers have identified compounds ... disease, a finding that may eventually lead to a ... degenerative nerve disorders. "Our studies have uncovered a ... for other neurodegenerative diseases," said Dr. Ilya Bezprozvanny, professor ...
... A new study conducted by a team of ... light on a possible new approach to treat the ... enzyme that connects extracellular fibers. The study, published online ... the direction of Katya Ravid, PhD, professor of medicine ...
... MARC (Minority Access to Research Careers) Program has announced the ... of Reproduction (SSR) Annual Meeting in Portland, Oregon from July ... to promote the entry of underrepresented minority students, postdoctorates and ... to encourage the participation of young scientists at the 2011 ...
Cached Biology News:Compound may provide drug therapy approach for Huntington's disease 2BUSM study identifies new potential approaches to treat myelofibrosis 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The DSQ II (Dual-Stage Quadrupole) ... the world leader in analytical instrumentation, introduces ... the DSQ II. Based on the ... DSQ and PolarisQ GC/MS systems, the DSQ ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: